Allos Therapeutics Inc. (NASDAQ:ALTH) suffered a setback when the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) reiterated the negative opinion issued by it in January 2012, regarding the conditional approval of Allos’ sole marketed product, Folotyn (pralatrexate injection), in the EU.
Allos is looking to get Folotyn approved in the EU for treating patients suffering from peripheral T-cell lymphoma (PTCL) whose disease progressed after at least one … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards